On the Application of Artificial Intelligence/Machine Learning (AI/ML) in Late-Stage Clinical Development.

Autor: Köchert K; Bayer AG, Berlin, Germany., Friede T; Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.; DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany., Kunz M; Bayer AG, Berlin, Germany. michael.kunz@bayer.com., Pang H; Genentech, South San Francisco, CA, USA., Zhou Y; Vertex Pharmaceuticals, Boston, MA, USA., Rantou E; Office of Biostatistics, FDA/CDER/OTS, Silver Spring, MD, USA.

Publikováno v: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2024 Nov; Vol. 58 (6), pp. 1080-1093. Date of Electronic Publication: 2024 Aug 21.

PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)

Autor: Lambrechts, D., Koechert, K., Schulz, A., Vonk, R., Rutstein, M., Kobina, S., Grothey, A., Van Cutsem, E., Teufel, M.

Publikováno v: In Annals of Oncology June 2016 27 Supplement 2:ii102-ii102

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.

Autor: Kindler HL; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. Electronic address: hkindler@medicine.bsd.uchicago.edu., Novello S; Department of Oncology, University of Turin, Orbassano, Turin, Italy., Bearz A; Department of Medical Oncology and Immune-Related Cancers, CRO-IRCCS Centro di Riferimento Oncologico di Aviano, Aviano, Italy., Ceresoli GL; Department of Medical Oncology, Oncology Unit, Cliniche Humanitas Gavazzeni, Bergamo, Italy., Aerts JGJV; Department of Pulmonary Medicine, Erasmus MC Cancer Centre, Rotterdam, Netherlands., Spicer J; Comprehensive Cancer Centre, King's College London, London, UK., Taylor P; Department of Medical Oncology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK., Nackaerts K; Laboratory of Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, Universitair Ziekenhuis Leuven, KU Leuven, Leuven, Belgium., Greystoke A; Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne, UK., Jennens R; Epworth Cancer Services Clinical Institute, Epworth Healthcare, Richmond, VIC, Australia., Calabrò L; Department of Oncology, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., Burgers JA; Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands., Santoro A; Humanitas University, Milan, Italy; Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy., Cedrés S; Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain., Serwatowski P; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Ponce S; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Van Meerbeeck JP; Department of Thoracic Oncology, Antwerp University and University Hospital and European Reference Network for Rare or Low Prevalence Complex Disease (ERN-LUNG), Antwerp, Belgium., Nowak AK; Medical School, University of Western Australia, Perth, WA, Australia; National Centre for Asbestos Related Diseases, Institute for Respiratory Health, Perth, WA, Australia., Blumenschein G Jr; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Siegel JM; Clinical Statistics Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Kasten L; Statistics, Syneos Health Clinical Solutions, Morrisville, NC, USA., Köchert K; Biomarker and Data Insights, Bayer AG Pharma, Berlin, Germany., Walter AO; Translational Medicine Oncology, Bayer AG Pharma, Berlin, Germany., Childs BH; Oncology Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Elbi C; Global Clinical Development, Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Hassan R; Department of Thoracic and GI Malignancies, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fennell DA; Leicester Cancer Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address: df132@leicester.ac.uk.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2022 Apr; Vol. 23 (4), pp. 540-552.

Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL).

Autor: Wurster KD; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Costanza M; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Kreher S; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Glaser S; Institute of Human Genetics, Ulm University, Ulm University Medical Center, 89081 Ulm, Germany., Lamprecht B; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Schleussner N; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Anagnostopoulos I; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Hummel M; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Jöhrens K; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Stein H; Pathodiagnostik Berlin, 12099 Berlin, Germany., Molina A; Sutro Biopharma, South San Francisco, CA 94080, USA., Diepstra A; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands., Gillissen B; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13125 Berlin, Germany., Köchert K; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Siebert R; Institute of Human Genetics, Ulm University, Ulm University Medical Center, 89081 Ulm, Germany., Merkel O; Unit of Experimental and Laboratory Animal Pathology, Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.; European Research Initiative on ALK-related malignancies (ERIA), 1090 Vienna, Austria., Kenner L; Unit of Experimental and Laboratory Animal Pathology, Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.; European Research Initiative on ALK-related malignancies (ERIA), 1090 Vienna, Austria., Janz M; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany., Mathas S; Max-Delbrück-Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12200 Berlin, Germany.; Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125 Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; European Research Initiative on ALK-related malignancies (ERIA), 1090 Vienna, Austria.

Publikováno v: Cancers [Cancers (Basel)] 2021 Oct 07; Vol. 13 (19). Date of Electronic Publication: 2021 Oct 07.

465P Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial

Autor: Battaglin, F., Zhang, W., Skubala, A., Arai, H., Wang, J., Soni, S., Wang, Y.A., Köchert, K., Schulz, A., Teufel, M., Millstein, J., Lenz, H.J.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S439-S439